By Sheeba M. | Weedstock Market Desk | October 23, 2026 — 2:00 PM ET
Cannabis equities are heading into the final session of the week with a mixed tone as investors digest a busy Q3 earnings season and await fresh catalysts on the regulatory front. Here is your Friday afternoon check-in on the names moving markets today.
Today’s Top Movers
Tilray Brands (TLRY) is the standout gainer early Friday, trading up roughly 4.8% on above-average volume. The move follows constructive commentary from management at an investor conference Thursday evening, where executives reiterated confidence in the company’s European medical cannabis distribution network and flagged improving gross margins in its Canadian recreational segment. Tilray has struggled to hold gains through much of 2026, so bulls will be watching closely to see whether today’s momentum carries into the close.
Organigram Holdings (OGI) is also showing relative strength Friday, up approximately 3.2% after the company’s UK partner published positive Phase II clinical data for its medical cannabinoid formulation late Thursday. That binary event had been a known near-term catalyst for Organigram, and the favorable read-through is drawing renewed interest from biotech-crossover investors who have largely avoided the Canadian LP space.
Canopy Growth (CGC) is the notable laggard today, sliding around 6.1% intraday as the company disclosed it is exploring additional cost-reduction measures amid continued cash burn in its U.S. THC operations. Canopy has been the most volatile name in the LP cohort in 2026, and today’s selling pressure underscores persistent skepticism about its path to profitability without a meaningful U.S. federal reform catalyst.
Among U.S. multistate operators, AYR Wellness (AYRWF) is drawing attention after reporting a narrower-than-expected adjusted EBITDA loss for Q3 and announcing a strategic review of its Massachusetts and New Jersey retail footprint. The stock is trading up roughly 5.5%, though it remains well below its 52-week high. Investors are treating this as a tentative sign that management is getting more serious about capital discipline.
Macro Backdrop
The broader equity market is posting modest gains Friday after a stronger-than-expected jobs report confirmed that the Federal Reserve’s soft-landing scenario remains intact heading into year-end. Cannabis equities have historically shown limited correlation with the broader tape on a day-to-day basis, but a risk-on sentiment across small-cap growth names is providing a marginal tailwind today.
The U.S. dollar is slightly weaker on the week, which is incrementally positive for Canadian LP names that report in Canadian dollars but are priced in USD for American investors. That currency dynamic has been a quiet headwind for TLRY, OGI, and CGC holders through much of the third quarter, so any reversal here could help restore some valuation credibility in the LP cohort.
Regulatory Watch
No major federal regulatory developments have crossed the wire this morning, but market participants continue to track the DEA administrative law judge proceedings related to cannabis rescheduling. Legal observers monitoring the docket note that scheduling arguments could resume as early as mid-November, which would represent the next meaningful opportunity for a procedural update. Any signal of an accelerated timeline would likely serve as a meaningful catalyst for the MSO cohort in particular, given that Schedule III status would unlock Section 280E tax relief for federally compliant operators.
In state-level news, Ohio regulators posted updated adult-use retail licensing guidance Friday morning, clarifying application windows for municipalities that had opted into cannabis sales under the 2023 voter initiative but had not yet completed local approval processes. Ohio is shaping up as a meaningful revenue contributor for several MSOs with existing medical operations in the state, and today’s guidance reduces one layer of regulatory uncertainty for operators planning 2027 expansion capital.
Sector Sentiment
The MSOS ETF, the primary institutional vehicle for U.S. cannabis equity exposure, is trading modestly higher Friday with volume in line with its 20-day average. The ETF’s relative performance has improved through Q3 earnings season, as several of its core holdings delivered results that beat subdued expectations. However, the fund remains approximately 18% below its early-2026 high, reflecting the persistent uncertainty that comes with operating in a federally illegal industry.
If you are tracking specific names in your own portfolio, our cannabis stock tracker is updated throughout the trading day with price data, 52-week ranges, and sector comparisons across the major MSOs and Canadian LPs.
Week Ahead
With Q3 earnings season largely wrapped for the major MSOs, the macro calendar thins out significantly next week. The primary focus will shift back to regulatory developments, state-level expansion activity, and any M&A signals from operators using their strengthened balance sheets opportunistically. Watch for Trulieve’s updated strategic roadmap presentation scheduled for late October, and keep an eye on Pennsylvania where adult-use legalization momentum is building ahead of what could be a pivotal legislative window in early 2027.
Have a productive close to the trading week. We will be back with the full end-of-day recap this evening.
Sheeba M. covers cannabis equities and regulatory affairs for Weedstock. Nothing published here constitutes investment advice. Always conduct your own due diligence.